Company intelligence / Profile preview

Guard Therapeutics

Stockholm, Swedenguardtherapeutics.com ↗

Ownership: Private
Employees: ~12
Development stage: Phase 2

Overview

Guard Therapeutics’ lead candidate, RMC-035, a recombinant alpha‑1‑microglobulin protein, has completed patient enrollment in the Phase 2b POINTER study for prevention of acute kidney injury in high-risk patients undergoing open-heart surgery. The company has reported positive safety reviews and clinically validated proof of concept. RMC‑035 holds FDA Fast Track Designation and IND clearance.

Therapeutic areas: Nephrology
Modalities: Recombinant proteinPeptidesBiologic
Industry: Biotech

Drug pipeline

1 asset

ROSgard

Phase 2

Indications: Acute kidney injury, Cardiac surgery-associated acute kidney injury

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Guard Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guard Therapeutics.